Suehiro T, Yamamoto M, Yoshida K, Ohno F
Second Department of Internal Medicine, Kochi Medical School, Japan.
Clin Chem. 1993 Jan;39(1):60-5.
We determine the concentration of proapolipoprotein (proapo) A-I and its ratio with total apolipoprotein (apo) A-I (proapo A-I/total apo A-I) in plasma of patients with liver disease; we used a noncompetitive sandwich method, an enzyme-linked immunosorbent assay. The mean (SD) proapo A-I concentrations in patients with decompensated or compensated liver cirrhosis were higher than in normal subjects: 88 (25), 105 (36), and 69 (25) mg/L, respectively. The mean (SD) ratio (expressed as %) for each of these types of liver cirrhosis was also higher than in normal subjects: 10.0 (3.5), 10.2 (3.9), and 4.6 (1.6), respectively. In the patients, the proapo A-I concentration was positively correlated with the concentration of high-density lipoprotein subtype 2 cholesterol (HDL2-C) (r = 0.736), and the proapo A-I/total apo A-I ratio was correlated inversely with the HDL3-C concentration (r = -0.609). The activity of proapo A-I converting enzyme in patients with liver cirrhosis (62 +/- 30 nmol/h per liter) was significantly (P < 0.01) lower than that in normal subjects (172 +/- 55 nmol/h per liter). The increases of the plasma proapo A-I concentration and ratio in patients with liver cirrhosis may be caused by a decreased production of the converting enzyme in the liver. The increase of plasma proapo A-I may thus also affect the circulating HDL subtypes.
我们测定了肝病患者血浆中前载脂蛋白(proapo)A-I的浓度及其与总载脂蛋白(apo)A-I的比值(proapo A-I/总apo A-I);我们采用了一种非竞争性夹心方法,即酶联免疫吸附测定法。失代偿期或代偿期肝硬化患者的平均(标准差)proapo A-I浓度高于正常受试者,分别为88(25)、105(36)和69(25)mg/L。这些类型的肝硬化患者各自的平均(标准差)比值(以%表示)也高于正常受试者,分别为10.0(3.5)、10.2(3.9)和4.6(1.6)。在患者中,proapo A-I浓度与高密度脂蛋白2型胆固醇(HDL2-C)浓度呈正相关(r = 0.736),而proapo A-I/总apo A-I比值与HDL3-C浓度呈负相关(r = -0.609)。肝硬化患者中proapo A-I转换酶的活性(62±30 nmol/h每升)显著低于正常受试者(172±55 nmol/h每升)(P < 0.01)。肝硬化患者血浆proapo A-I浓度和比值的升高可能是由于肝脏中转换酶产生减少所致。因此,血浆proapo A-I的升高也可能影响循环中的HDL亚型。